FATE News and Press, Fate Therapeutics Inc. From 02/28/22

Enrollment Ongoing in Multi-dose, Multi-cycle Escalation Cohort of FT596+R at 900 Million Cells per Dose for R/R BCL; Interim Phase 1 Data of 16 Patients Showed 69% ORR and 56% CR in Single-dose Escalation Cohorts of FT596+R at ≥90 Million Cells Granted RMAT Designation f...

ACAD,ACHC,AGM,AMBA,AMRC,OTCPK:AOIFF,APLS,APPF,APTS,ARCT,ARDX,ASXC,ATRA,AVIR,AY,BANX,BIGC,BLFS,BLNK,BRMK,CAPL,CLDX,CO,CSR,CSTL,DAR,DDD,DNMR,DVAX,ENDP,EVA,FATE,FGEN,FRPT,FSK,GAIA,GDRX,GMRE,GOEV,GPOR,GRPN,HHC,HPQ,HRTX,ICAD,KD,LAZR,LCID,MBI,MDXG,MRTX,NKTR,NMFC,NVAX,NVEE,OCUL,OKE,ONTF,OTIC,PDCE,PG...

Fate Therapeutics (NASDAQ:FATE) is scheduled to announce Q4 earnings results on Monday, Feb. 28, after market close. The consensus EPS estimate is -$0.66 and the consensus revenue estimate is $11.55M (-27.4% Y/Y). Over the last 1 year, FATE has beaten EPS estimates 25% of the time and has bea...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q4-2021 13F filings the consensus holdings were updated, 7 stocks were removed and 7 added from the unive...

Gainers: Renewable Energy Group REGI +34%. Golden Entertainment (NASDAQ:GDEN) +17%. Homology Medicines (NASDAQ:FIXX) +7%. Cara Therapeutics CARA +5%. Arcimoto (NASDAQ:FUV) +5%. Losers: Fate Therapeutics (NASDAQ:FATE) -5%. CSP  (NASDAQ:CSPI) -3%. ImmunityBio  (NAS...

Fate's ASH data has allayed concerns about durability through multiple dosing. More needs to be seen before a registrational trial can be planned. However, things aren't going too badly. For further details see: Fate Therapeutics: Slowly Getting To An Attractive Position...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q3-2021 13F filings the consensus holdings were updated, 5 stocks were removed and 5 added from the unive...

SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cance...

The following slide deck was published by Fate Therapeutics, Inc. in conjunction with this event. For further details see: Fate Therapeutics (FATE) Investor Presentation - Slideshow

SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, to...